

# Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538  
09 March 2020 11:00:00 CET - Lund, Sweden



## NeuroVive – company presentations March/April 2020

### **NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) informs about its scheduled company presentations for March and April 2020.**

Since the Board of Directors of NeuroVive Pharmaceutical AB on Wednesday, 19 February, 2020 decided to propose a preferential rights issue with a subscription period from 6 April, 2020 until 24 April, 2020, the Company wishes to provide information about upcoming company presentations by NeuroVive in March and April 2020.

NeuroVive's CEO Erik Kinnman will present the company and its business at the following events. For more information, follow the links indicated below.

#### **Wednesday 11 March: Stockholm Corporate Finance 12th Life Science seminar 2020, Stockholm**

Berns (Kammarsalen), Berzelii park, at 07.30 a.m. – 12.15 p.m.

<https://stockholmcorp.se/stockholm-corporate-finance-12e-life-science-seminarium/>

#### **Thursday 12 March: Bolagsdag, Erik Penser Bank, Stockholm**

Erik Penser Bank, Apelbergsgatan 27, at 10.00 a.m. – approx. 6.00 p.m.

Register to [bolagsdag@penser.se](mailto:bolagsdag@penser.se) no later than 9 March

#### **Tuesday 31 March: Redeye Digital Investor Forum, Stockholm**

Redeye, Mäster Samuelsgatan 42, at 1.00 p.m. – 3.00 p.m.

<https://www.redeye.se/events#/event/585691>

#### **Tuesday 21 April: Redeye Investor After Work, Gothenburg**

Scandic Rubinen, Kungsportsavenyn 24, at 5.30 p.m. – 9.00 p.m.

<https://www.redeye.se/events#/>

For information about the Company and the preferential rights issue, two interviews with NeuroVive's CEO Erik Kinnman are available:

- BioStock (in Swedish): <https://www.biostock.se/2020/02/neurovives-vd-om-den-kommande-emissionen/>
- Redeye (in English): <https://www.redeye.se/research/585670/neurovive-interview-ceo-erik-kinnman-video>

# Press Release

NeuroVive Pharmaceutical AB (publ), 556595-6538  
09 March 2020 11:00:00 CET - Lund, Sweden

---



## Contacts

---

Catharina Johansson, CFO, IR & Communications  
+46 (0)46-275 62 21, [ir@neurovive.com](mailto:ir@neurovive.com)

### NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46 (0)46 275 62 20 (switchboard)

[info@neurovive.com](mailto:info@neurovive.com), [www.neurovive.com](http://www.neurovive.com)

For news subscription, please visit <http://www.neurovive.com/press-releases/subscription-page/>

Follow us on [LinkedIn](#)

Subscribe to our [YouTube channel](#)

## About Us

---

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTC Market's Pink Open market in the US (OTC: NEVPF).

## Attachments

---

[NeuroVive – company presentations March/April 2020](#)